The Trump administration, through the U.S. Department of Health and Human Services (HHS), allows compounding pharmacies to make and sell six peptides that have not yet been approved by the Food and Drug Administration (FDA). The change is framed as using enforcement discretion rather than finalizing new approvals or making regulatory changes, and outlets note it may still be insufficient to meet patient demand.
NPR and The Hill both describe HHS’s notice permitting compounding pharmacies to manufacture these specific peptides while they remain under FDA review. NPR emphasizes the practical effect on availability and suggests the number of pharmacies or output may not fully satisfy demand. The Hill highlights that HHS gives compounding pharmacies “free rein” within this limited set of peptides and foregrounds the policy rationale connected to expanded access advocated by groups aligned with the MAHA agenda.
Overall, the reporting focuses on what HHS is allowing, how it is being implemented administratively, and the potential impact on access to peptides that are not yet FDA-approved.
